Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan

被引:4
作者
Aronow, Herbert D. [1 ]
Dutro, Michael P. [2 ]
Kuznik, Andreas [2 ]
Cwengros, James [2 ]
机构
[1] St Joseph Mercy Hosp, Michigan Heart & Vasc Inst, Clin Scholars Program, Ann Arbor, MI 48104 USA
[2] Pfizer Inc, Pfizer Global Med, New York, NY USA
关键词
Cardiovascular diseases; Dyslipidemia; Managed care; Statins; BLOOD-PRESSURE; SECONDARY PREVENTION; SERUM-CHOLESTEROL; HEART-FAILURE; CORONARY; DISEASE; ATORVASTATIN; HYPERTENSION; THERAPY; UPDATE;
D O I
10.1185/03007990802611828
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although statins are widely used for the prevention and management of cardiovascular disease in patients with dyslipidemia, the prevalence of cardiovascular comorbidities among statin users has not been well studied. Objective: To assess the prevalence of cardiovascular comorbidities, use of concomitant medications, interventions for managing the comorbidities, and hospitalization rates among statin users in Medicare and commercial health plan populations in the United States. Research design and methods: This retrospective study assessed pharmacy and medical claims of Medicare and commercial health plan members between 4/1/2005 and 3/31/2006. Patients with at least one claim for a statin were included in the analyses. Comorbidities and procedures were identified based on the presence of at least one diagnosis or procedure code. Results: Of the continuously eligible 238 900 Medicare and 3 258 266 commercial health plan members, 51 818 (21.7%) and 285 820 (8.8%) were statin users. Among the Medicare and commercial statin users, 62.4% and 41.8% were classified with either coronary heart disease (CHD), angina, diabetes mellitus, stroke, transient ischemic attack, or chronic kidney disease. Only 9.2% of Medicare and 29.2% of commercial statin users were not classified with hypertension or any of the comorbidities listed above. Of those with diabetes mellitus, 28.1% of Medicare and 15.9% of commercial statin users appeared to have received no pharmacotherapy for this condition. During the study period, 20.3% of Medicare and 10.3% of commercial statin users were reported to be hospitalized; 24.1% and 30.0% were admitted due to CHD/angina. Limitations: The study design was descriptive in nature and did not allow for demonstration of cause and effect between diagnoses, treatments, and outcomes. Conclusions: This study highlights that statin users have a high frequency of cardiovascular comorbidities and are at high risk for cardiovascular events. Comorbidity-related hospitalizations are common, yet interventions for managing many of these comorbidities may be underutilized.
引用
收藏
页码:205 / 213
页数:9
相关论文
共 41 条
[1]   Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack [J].
Adams, Robert J. ;
Albers, Greg ;
Alberts, Mark J. ;
Benavente, Oscar ;
Furie, Karen ;
Goldstein, Larry B. ;
Gorelick, Philip ;
Halperin, Jonathan ;
Harbaugh, Robert ;
Johnston, S. Claiborne ;
Katzan, Irene ;
Kelly-Hayes, Margaret ;
Kenton, Edgar J. ;
Marks, Michael ;
Sacco, Ralph L. ;
Schwamm, Lee H. .
STROKE, 2008, 39 (05) :1647-1652
[2]  
[Anonymous], 2003, Am J Kidney Dis, V41, pI
[3]  
[Anonymous], DIABETES CARE S1
[4]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[5]   International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis [J].
Bhatt, DL ;
Steg, PG ;
Ohman, EM ;
Hirsch, AT ;
Ikeda, Y ;
Mas, JL ;
Goto, S ;
Liau, CS ;
Richard, AJ ;
Röther, J ;
Wilson, PWF ;
Andersen-Dalheim, H ;
Anderson, P ;
Anell, B ;
Arber, S ;
Armstrong, K ;
Arnot, D ;
Baldam, A ;
Barratt, I ;
Barresi, S ;
Beder, J ;
Benson, M ;
Bergman, F ;
Best, J ;
Bhasim, R ;
Bovell, G ;
Bowman, N ;
Brkic, M ;
Bromberger, D ;
Brown, D ;
Brown, J ;
Brownstein, M ;
Bruce, A ;
Buonopane, J ;
Burns, S ;
Butler, A ;
Byrne, D ;
Carson, J ;
Cassimatis, P ;
Chaffey, G ;
Chambers, D ;
Chan, WJ ;
Chan, B ;
Cheatham, J ;
Chen, R ;
Cheong, B ;
Cheung, C ;
Chin, J ;
Chiu, A ;
Choo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02) :180-189
[6]   Impact of adherence to statins on coronary artery disease in primary prevention [J].
Bouchard, Marie-Helene ;
Dragomir, Alice ;
Blais, Lucie ;
Berard, Anick ;
Pilon, Danielle ;
Perreault, Sylvie .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) :698-708
[7]  
CANDRILLI SD, 2007, AM COLL PHARM ANN M
[8]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[9]   Trends in serum lipids and lipoproteins of adults, 1960-2002 [J].
Carroll, MD ;
Lacher, DA ;
Sorlie, PD ;
Cleeman, JI ;
Gordon, DJ ;
Wolz, M ;
Grundy, SM ;
Johnson, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1773-1781
[10]  
CHOBANIAN AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI DOI 10.1161/01.HYP.0000107251.49515.C2